We need a common language, say researchers
Added: Thursday 18 August 2011
This month's EJC News Focus looks at the assessment of toxicities in Phase 1 trials of molecular treatments for cancer. Jean-Charles Soria explains that the principles underlying this area of research are up to 50 years old. He makes the case for a consensus and a "common language" for describing and assessing toxicities.
In order to be able to see the content from the www.medscape.com pages, please create first a free account at following link: